{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04431934: Not Applicable Interventional Unknown status CARRIER STATE
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:emilimogene sigulactibac [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00767988: Phase 2 Interventional Withdrawn Urinary Tract Infection
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03151967: Phase 2/Phase 3 Interventional Completed Urinary Tract Infections (UTI's)
(2015)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04431934: Not Applicable Interventional Unknown status CARRIER STATE
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04431934: Not Applicable Interventional Unknown status CARRIER STATE
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03057054: Phase 3 Interventional Active, not recruiting Hematopoietic and Lymphoid System Neoplasm
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04431934: Not Applicable Interventional Unknown status CARRIER STATE
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00561535: Phase 2 Interventional Completed Irritable Bowel Syndrome
(2007)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01007331: Not Applicable Interventional Completed Atopic Dermatitis
(2006)
Source URL:
Class:
STRUCTURALLY DIVERSE